10th Anniversary of Biomedicines—Advances in Mesenchymal Stem Cells

Message from the Guest Editors

The year 2022 marks the 10th anniversary of *Biomedicines*, a peer-reviewed, open-access journal in the biomedical field. So far, *Biomedicines* has published more than 2700 papers from more than 17,000 authors. We appreciate each author, reviewer, and academic editor whose support has brought us to where we are today.

To celebrate this significant milestone, we aim to publish a Special Issue entitled 10th Anniversary of *Biomedicines*—Advances in Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) represent a promising candidate source for cell therapies due to their effects on tissue and organ homeostasis; revascularization and tissue repair; as well as their immunomodulatory, anti-inflammatory, pro-angiogenic, pleiotropic, and tropic abilities. For this reason, considerable efforts have been made to introduce advanced MSCs-based therapy into clinical practice. This Special Issue is seeking to collect the latest innovative findings and achievements in the field of MSCs-based therapy.

Deadline for manuscript submissions: closed (31 May 2023)
Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

**Open Access:**— free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous]*)

Contact Us

*Biomedicines*
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
@Biomed_MDPI